Literature DB >> 32503680

Elevation of plasma angiotensin II level is a potential pathogenesis for the critically ill COVID-19 patients.

Zhiyong Wu1, Rui Hu2, Cuizhen Zhang3, Wei Ren2, Anfeng Yu2, Xiaoyang Zhou4.   

Abstract

Entities:  

Keywords:  ACE2; Angiotensin II; COVID-19; SARS-CoV-2

Mesh:

Substances:

Year:  2020        PMID: 32503680      PMCID: PMC7273814          DOI: 10.1186/s13054-020-03015-0

Source DB:  PubMed          Journal:  Crit Care        ISSN: 1364-8535            Impact factor:   9.097


× No keyword cloud information.
Little is known about the mechanism of coronavirus disease 2019 (COVID-19)-induced critical illness and death. The host infection mediated by SARS-CoV-2 is mainly relied on ACE2 receptor. There is still a lack of clinical data about the effects of interaction of ACE2 and SARS-CoV-2 on RAS system and disease progression. We investigated the plasma angiotensin II (Ang II) and renin levels in 82 non-hypertensive patients (42 mild cases, 25 severe cases, and 15 critically ill cases) infected by SARS-CoV-2 and 12 critically ill patients not infected by SARS-CoV-2 serving as control. Plasma Ang II level was higher than that of normal range in the majority of COVID-19 cases (90.2%), especially the plasma Ang II positive rate in the critically ill COVID-19 patients (100%). Plasma Ang II level in critically ill COVID-19 patients was significantly higher than that of control and those with mild COVID-19 symptoms (Fig. 1). Univariate analysis indicated a positive correlation between plasma Ang II level and COVID-19 severity.
Fig. 1

The positive rate and concentration of plasma renin and Ang II in different groups. a There were no statistical differences in the concentration of renin in patients with different severity of COVID-19. b The plasma Ang II concentration in the critically ill COVID-19 cases and severe COVID-19 cases was significantly higher than that of the mild COVID-19 cases. c, d The renin and Ang II positive rate in the three groups showed no statistical difference. e There was no statistical difference in the concentration of renin in patients with critically ill COVID-19 compared with the control. f The plasma Ang II concentration in the critically ill COVID-19 cases was significantly higher than that of control. g The renin positive rate in the two groups showed no statistical difference. h The plasma Ang II positive rate in the critically ill COVID-19 cases was significantly higher than that of control. Control: critically ill non-COVID-19 cases. *P < 0.05, **P < 0.01

The positive rate and concentration of plasma renin and Ang II in different groups. a There were no statistical differences in the concentration of renin in patients with different severity of COVID-19. b The plasma Ang II concentration in the critically ill COVID-19 cases and severe COVID-19 cases was significantly higher than that of the mild COVID-19 cases. c, d The renin and Ang II positive rate in the three groups showed no statistical difference. e There was no statistical difference in the concentration of renin in patients with critically ill COVID-19 compared with the control. f The plasma Ang II concentration in the critically ill COVID-19 cases was significantly higher than that of control. g The renin positive rate in the two groups showed no statistical difference. h The plasma Ang II positive rate in the critically ill COVID-19 cases was significantly higher than that of control. Control: critically ill non-COVID-19 cases. *P < 0.05, **P < 0.01 Partial SARS-CoV-2 patients (12.2%) showed elevation of renin content than normal range. There were no statistical differences in renin among the mild, severe, and critically ill COVID-19 patients and control (Fig. 1). These indicated that plasma Ang II elevation was closely related to the SARS-CoV-2 infection, which may be triggered by the interaction between S protein and ACE2 [1, 2]. This played important roles in COVID-19 progression. Previous study showed that subcutaneous Ang II infusion using osmotic pumps for 3 days led to decline of oxygenation and obvious pulmonary injuries after infusion of Ang II for 1 week [3]. For the mechanism, Ang II could promote apoptosis and skeleton reconstruction of pulmonary microvascular endothelial cells, hampering pulmonary microvascular endothelial barrier and the subsequent elevation of pulmonary exudate. This was extremely similar with the quarantine period and pathological manifestations of COVID-19 [4, 5]. Previous study [3] indicated that IL-22 could attenuate Ang II-induced pulmonary injury through modulating JAK2/STAT3 signaling pathway, which may provide new options for treating COVID-19. Therefore, elevation of Ang II triggered by interaction between ACE2 and S protein of SARS-CoV-2 may be important pathogenic factors for critically ill COVID-19 patients.
  5 in total

1.  VE-cadherin involved in the pulmonary microvascular endothelial cell barrier injury induced by angiotensin II through modulating the cellular apoptosis and skeletal rearrangement.

Authors:  Zhiyong Wu; Huagang Liu; Wei Ren; Feifeng Dai; Jinxing Chang; Bowen Li
Journal:  Am J Transl Res       Date:  2016-10-15       Impact factor: 4.060

2.  A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome.

Authors:  Akram Khan; Cody Benthin; Brian Zeno; Timothy E Albertson; John Boyd; Jason D Christie; Richard Hall; Germain Poirier; Juan J Ronco; Mark Tidswell; Kelly Hardes; William M Powley; Tracey J Wright; Sarah K Siederer; David A Fairman; David A Lipson; Andrew I Bayliffe; Aili L Lazaar
Journal:  Crit Care       Date:  2017-09-07       Impact factor: 9.097

3.  Interleukin 22 attenuated angiotensin II induced acute lung injury through inhibiting the apoptosis of pulmonary microvascular endothelial cells.

Authors:  Zhiyong Wu; Zhipeng Hu; Xin Cai; Wei Ren; Feifeng Dai; Huagang Liu; Jinxing Chang; Bowen Li
Journal:  Sci Rep       Date:  2017-05-19       Impact factor: 4.379

4.  Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus.

Authors:  Yushun Wan; Jian Shang; Rachel Graham; Ralph S Baric; Fang Li
Journal:  J Virol       Date:  2020-03-17       Impact factor: 5.103

5.  COVID-19 and the RAAS-a potential role for angiotensin II?

Authors:  Laurence W Busse; Jonathan H Chow; Michael T McCurdy; Ashish K Khanna
Journal:  Crit Care       Date:  2020-04-07       Impact factor: 9.097

  5 in total
  38 in total

1.  Unquantifiably low aldosterone concentrations are prevalent in hospitalised COVID-19 patients but may not be revealed by chemiluminescent immunoassay.

Authors:  Martin Wiegand; David J Halsall; Sarah L Cowan; Kevin Taylor; Robert J B Goudie; Jacobus Preller; Mark Gurnell
Journal:  Endocr Connect       Date:  2022-10-14       Impact factor: 3.221

2.  Angiotensin II Promotes SARS-CoV-2 Infection via Upregulation of ACE2 in Human Bronchial Cells.

Authors:  Ilaria Caputo; Brasilina Caroccia; Ilaria Frasson; Elena Poggio; Stefania Zamberlan; Margherita Morpurgo; Teresa M Seccia; Tito Calì; Marisa Brini; Sara N Richter; Gian Paolo Rossi
Journal:  Int J Mol Sci       Date:  2022-05-04       Impact factor: 6.208

Review 3.  Potential of Endogenous Oxytocin in Endocrine Treatment and Prevention of COVID-19.

Authors:  Stephani C Wang; Fengmin Zhang; Hui Zhu; Haipeng Yang; Yang Liu; Ping Wang; Vladimir Parpura; Yu-Feng Wang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-03       Impact factor: 6.055

4.  Plasma Angiotensin II Is Increased in Critical Coronavirus Disease 2019.

Authors:  Rafael L Camargo; Bruna Bombassaro; Milena Monfort-Pires; Eli Mansour; Andre C Palma; Luciana C Ribeiro; Raisa G Ulaf; Ana Flavia Bernardes; Thyago A Nunes; Marcus V Agrela; Rachel P Dertkigil; Sergio S Dertkigil; Eliana P Araujo; Wilson Nadruz; Maria Luiza Moretti; Licio A Velloso; Andrei C Sposito
Journal:  Front Cardiovasc Med       Date:  2022-06-24

Review 5.  ACE2-based decoy receptors for SARS coronavirus 2.

Authors:  Wenyang Jing; Erik Procko
Journal:  Proteins       Date:  2021-05-18

6.  An Open Label Trial to Assess Safety of Losartan for Treating Worsening Respiratory Illness in COVID-19.

Authors:  Charles D Bengtson; Robert N Montgomery; Usman Nazir; Lewis Satterwhite; Michael D Kim; Nathan C Bahr; Mario Castro; Nathalie Baumlin; Matthias Salathe
Journal:  Front Med (Lausanne)       Date:  2021-02-17

7.  Should we use angiotensin II infusion in COVID-19-associated vasoplegic shock?

Authors:  Karim Bendjelid
Journal:  Crit Care       Date:  2020-07-09       Impact factor: 9.097

Review 8.  The Prothrombotic State Associated with SARS-CoV-2 Infection: Pathophysiological Aspects.

Authors:  Nicola Semeraro; Mario Colucci
Journal:  Mediterr J Hematol Infect Dis       Date:  2021-07-01       Impact factor: 2.576

Review 9.  The Role and Therapeutic Potential of NF-kappa-B Pathway in Severe COVID-19 Patients.

Authors:  Apurva Hariharan; Abdul Rahman Hakeem; Subathra Radhakrishnan; Mettu Srinivas Reddy; Mohamed Rela
Journal:  Inflammopharmacology       Date:  2020-11-07       Impact factor: 4.473

Review 10.  Unraveling the Mystery Surrounding Post-Acute Sequelae of COVID-19.

Authors:  Rakhee K Ramakrishnan; Tarek Kashour; Qutayba Hamid; Rabih Halwani; Imad M Tleyjeh
Journal:  Front Immunol       Date:  2021-06-30       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.